Advertisement
Advertisement
REVB
Revelation Biosciences, Inc. Common Stock
1.13
USDSponsored
-0.01
-0.88%
Aug 10, 15:59 UTC -4
Closed
After-Market
1.18
+0.05
+4.42%
REVB Earnings Reports
Positive Surprise Ratio
REVB beat 10 of 18 last estimates.
56%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.82
Implied change from Q2 26 (Revenue/ EPS)
--
/-5.75%
Implied change from Q3 25 (Revenue/ EPS)
--
/-88.42%
Revelation Biosciences, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, REVB reported earnings of -0.87 USD per share (EPS) for Q2 26, missing the estimate of -0.84 USD, resulting in a -2.76% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.79% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.82 USD, with revenue projected to reach -- USD, implying an decrease of -5.75% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were Revelation Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Revelation Biosciences, Inc. Common Stock reported EPS of -$0.87, missing estimates by -2.76%, and revenue of $0.00, 0% as expectations.
How did the market react to Revelation Biosciences, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 1.79%, changed from $1.12 before the earnings release to $1.14 the day after.
When is Revelation Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Revelation Biosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, Revelation Biosciences, Inc. Common Stock is expected to report EPS of -$0.82 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement